Pancreatic Adenocarcinoma Metastatic
Conditions
Brief summary
The present project aims to elucidate the metabolic interactions within the tumor microenvironment of pancreatic adenocarcinoma, both in the primary tumor and in hepatic and pulmonary metastatic sites, as well as in circulating blood biomarkers. Deciphering these complex interactions aims to identify exploitable vulnerabilities for predicting treatment efficacy or for guiding therapeutic strategies.
Detailed description
Pancreatic adenocarcinoma (PDAC) remains one of the deadliest cancers, with survival rarely exceeding a few months and limited progress despite improved chemotherapy. Its poor prognosis is driven by late diagnosis, therapeutic resistance, and low responsiveness to targeted therapies and immunotherapy. PDAC is characterized by a dense, immunosuppressive stroma and severe metabolic stress due to poor vascularization. Tumor progression relies heavily on stromal cells-such as cancer-associated fibroblasts and macrophages-as well as metabolic adaptations of cancer cells. This project focuses on two key PDAC features to identify new biomarkers and therapeutic targets: * Stromal cell prevalence * Metabolic reprogramming
Interventions
OTHERBiopsy collection
Tumor cells isolation
OTHERBlood collection
Isolation of blood monocytes
Sponsors
Institut Paoli-Calmettes
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \> 18 years 2. Signed written informed consent specific to the PROMETAP study 3. Affiliation with a social security system 4. Treatment and follow-up performed at the Institut Paoli-Calmettes 5. Metastatic PDAC requiring biopsy as part of routine care (group1 and 2) 6. Prior treatment: * No previous chemotherapy for the "initial" group * No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group 7. Eligible for chemotherapy (ECOG \< 2) Non-Inclusion Criteria: 1. Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2) 2. Absence of a metastasis accessible to biopsy (group1 and 2) 3. Concurrent treatment for another active cancer 4. Pregnant or breastfeeding women 5. Patients in emergency situations 5\. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation and comparison of biological parameters reflecting metabolic alterations within the tumor microenvironment of pancreatic adenocarcinoma | From sample collection to completion of analyses, estimated at 3 years | * Assessment of stromal dependency mechanisms; * Characterization and comparison of the metabolic profiles of primary pancreatic tumors and associated liver and lung metastases. These analyses aim to identify potential therapeutic targets and to explore diagnostic, prognostic, and predictive biomarkers of treatment response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Exploratory characterization of metabolic pathways, tumor microenvironment features, and associated biomarkers in pancreatic adenocarcinoma. | From sample collection to completion of analyses, estimated at 3 years | * Identification of prognostic markers of therapeutic response originating from the tumor microenvironment. * Identification of mechanisms of resistance to anti-tumor treatments linked to the microenvironment. * Identification of new therapeutic strategies capable of specifically targeting the tumor microenvironment. |
Countries
France
Contacts
CONTACTJihane PAKRADOUNI
Outcome results
None listed